Matly David 4

What Happened

• Matly David, President of Inhibrx Biosciences (INBX), received a grant/award on 2026-04-24 covering 50,000 derivative shares (a stock option award) with an acquisition price of $0.00. This was an award of options (not an open-market buy or sale), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-04-24; Form 4 filed: 2026-04-27 (filed within the typical 2-business-day window).
• Security type: Derivative (stock option award) — 50,000 shares @ $0.00.
• Vesting: 25% of the option vests on April 24, 2027; the remainder vests in equal monthly installments over the following 36 months, subject to continued service. (Footnote from filing.)
• Shares owned after transaction: not specified in the provided Form 4 details.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate cashless exercise/sale in this filing.

Context

• This was a grant of stock options (a compensation award), which is a routine way companies compensate executives. Because the award vests over time, it aligns future incentive with continued service rather than signaling an immediate market view. Unlike purchases, grants do not require the insider to invest personal cash at the time of the award.